Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis

Authors

Institutions

Publication Details

Journal
The Lancet Oncology
Published
2024-10-19
DOI
https://doi.org/10.1016/s1470-2045(24)00457-1
Citations
54
Primary Topic
Hepatocellular Carcinoma Treatment and Prognosis
Type
article
Field-Weighted Citation Impact
19.95

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis

David James Pinato, Benjamin Adegbite, Maria Isabel Fiel, Antonio D’Alessio et al.
54 citations
The Lancet Oncology
Hepatocellular Carcinoma Treatment and Prognosis
19.95
article

Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis

David James Pinato, Benjamin Adegbite, Maria Isabel Fiel, Antonio D’Alessio, Ciro Celsa, Daniel Shu, Marina Baretti, Vincent Yip, Robert Goldin, Thomas U. Marron, Yung‐Yeh Su, Alessio Cortellini, Giulia Francesca Manfredi, Chiun Hsu, Bernardo Stefanini, Mark Yarchoan, Julia Blanter, Fionnuala Crowley, Robert Anders, Stephen C. Ward, Madhava Pai, Sarah Slater, Claudia Angela Maria Fulgenzi
article en
54 citations

Abstract

No abstract available for this paper.
The Lancet OncologyVol. 25(11)
Johns Hopkins University (US), Barts Health NHS Trust (GB), St Mary's Hospital (GB), Sidney Kimmel Comprehensive Cancer Center (US), Imperial College London (GB), Icahn School of Medicine at Mount Sinai (US)
Cancer Research Institute, Bristol-Myers Squibb, Pfizer, AstraZeneca, Sanofi, Fibrolamellar Cancer Foundation, Boston Scientific Corporation, Regeneron Pharmaceuticals, Wellcome Trust, Exelixis, Foundation for Liver Research, Celldex Therapeutics, Atara Biotherapeutics, Incyte, NGM Biopharmaceuticals, G1 Therapeutics, Glenmark Pharmaceuticals, Cancer Research UK, National Institute for Health and Care Research, Department of Health and Social Care, Eisai, Astellas Pharma, Associazione Italiana per la Ricerca sul Cancro, Fondazione Italiana per la Ricerca sul Cancro, European Association for the Study of the Liver, Ipsen, Da Volterra, National Science and Technology Council, National Institutes of Health, Genentech, EMD Serono, Chugai Pharmaceutical, Imperial Experimental Cancer Medicine Centre, NIHR Imperial Biomedical Research Centre, National Cancer Institute
Openalex Percentile: Top 0%
Hepatocellular Carcinoma Treatment and Prognosis
19.95
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.